A new paper highlights the contribution of IMI/IHI to paediatric research

The needs of children should be met by medical devices, diagnostics and medicines. The number of paediatric drugs approved by regulators has increased, but there are still gaps. Few medical devices or in vitrodiagnostics are specifically designed for children. This leads doctors to adapt adult devices to suit the needs of young patients.

In Frontiers in Medicine Nathalie Séigneuret, Senior Scientific Project manager at IHI, explains in Frontiers in Medicine how Innovative Medicines Initiative and IHI are progressing paediatrics research and producing results that have already made a significant difference in this difficult field. The IHI projects are well positioned to achieve this goal because they include all the key players in paediatrics research including regulators, academics, representatives from industry, children, and parents.

Improved paediatric clinical trial

The IMI/IHI project delivers tools and resources that facilitate paediatric trials.

  • Conect4children is a pan European clinical trial network consisting of 20 hubs in 21 different countries. This allows access to more than 250 clinical sites. Project outputs include data quality, feasibility of trials, and educational material.
  • INNODIA HARVEST and INNODIA have created a network of clinical studies for type 1 diabetes as well as a protocol master for prevention studies.
  • In order to carry on the projects started by conect4children, INNODIA has set up non profit foundations.
  • EU-PEARL has developed a framework and toolkit to help facilitate platform trials. One of the use cases for this project focused on Neurofibromatosis, a rare condition. These resources are now being used by the Children’s Tumor Foundation to create a platform to test treatment for NF.
  • RealiseD, a new IHI project, aims at developing playbooks for further optimising clinical trial designs which could be applied to rare paediatric disorders.
  • AIMS-2-TRIALS is creating a network of clinical sites for the autism spectrum disorder. It also identifies biomarker candidates that can be tested in clinical trials.

Improve paediatric cancer prevention

Better tools are urgently needed to study childhood tumors in the laboratory. IMI’s ITCC-P4 project created more than 450 models of paediatric cancers derived from patients. A majority of models were also fully characterized with blood and tumour samples taken from patients. ITCC-P4 GmbH, a company set up by the project, is a not-for-profit organisation that offers access to models used for testing assets against paediatric tumours.

Early diagnosis is possible through screening programmes

It is important to diagnose children early in order to maintain their health and minimise the risks of complications.

  • Screen4Care designs and runs a newborn genetic screening program to detect rare disease at its earliest stage.
  • EDENT1FI has created a pan-European screening platform for children and teenagers to detect those in the earliest stages or who are at high risk of type 1 diabetes.

Immunisation should be increased

IMI Projects provide knowledge and resources for improving vaccinations.

  • RESCEU and PROMISE have helped us to better understand respiratory syncytial viruses (RSVs) by providing tools and data to help optimise the introduction and use of RSV vaccinations for children and adults in Europe.
  • PERISCOPE tools for advancing pertussis development (whooping-cough) are being used today to assess the efficacy and safety of a new pertussis vaccination.

Looking to the Future

Nathalie writes: “IHI/IMI project have successfully delivered many achievements in European paediatrics research.” The results are revolutionizing paediatric research, with a wide range of achievements.

She concludes that, looking to the future: “At IHI’s halfway mark, it is time to concentrate our efforts in areas which will not only boost Europe’s competitiveness but also accelerate the development and implementation of innovative medical devices, diagnostics and other interventions to benefit the entire paediatric patient population, from newborns to adolescents.”

Download in PDF format
The above text is a summary of original content published on the website of the European Commission (or related institutions). Licensed under CC BY 4.0
FREE NEWSLETTERS
Sign up to our free, English language newsletter, and get notifications when EU news, upcoming events and/or new EU funding opportunities are published
FREE NEWSLETTERS
Sign up to our free, English language newsletters, and get notifications when EU news, upcoming events and/or new EU funding opportunities are published
There are now over 300 funding opportunities available on EUFundingPortal.eu
Sign up for our free English newsletter to receive notifications about current (open) funding opportunities from the EU and beyond, delivered 2-3 times a week!
Sign up for our free English newsletter to receive notifications about current (open) funding opportunities from the EU and beyond, delivered 2-3 times a week!
There are now over 300 funding opportunities available on EUFundingPortal.eu